FDA to review re-submitted Bristol-Myers hepatitis C drug

March 12 (Reuters) - Bristol-Myers Squibb Co said U.S. regulators have accepted the company's re-submitted marketing application for an experimental treatment for hepatitis C, following the drugmaker's decision last year to pull back its initial marketing request.